Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000947871-25-000610
Filing Date
2025-06-16
Accepted
2025-06-16 07:37:49
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 6263
  Complete submission text file 0000947871-25-000610.txt   7931
Mailing Address P.O. BOX 23224 DOHA S3 QATAR
Business Address OOREDOO TOWER (BUILDING 14), AL DAFNA ST (STREET 801) DOHA S3 QATAR 974 441 4466
Qatar Investment Authority (Filed by) CIK: 0001441449 (see all company filings)

EIN.: 000000000 | State of Incorp.: S3 | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 21 HICKORY DRIVE, SUITE 500 WALTHAM MA 02451
Business Address 21 HICKORY DRIVE, SUITE 500 WALTHAM MA 02451 617-819-2020
Sionna Therapeutics, Inc. (Subject) CIK: 0002036042 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94871 | Film No.: 251048541
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)